The fight for Liquid Gold

The update you need on the hoarding of Covid-19 vaccines and its distribution between the haves and the have nots

19th March, 2021

Countries with higher GDP were able to purchase a higher proportion of vaccines than poorer countries. The procurements announced by the USA, the UK, the EU and Canada account for over 55% of Covid-19 vaccines negotiated worldwide*, giving each of these countries (or groups of countries) the ability to cover their entire population twice. Meanwhile, countries in the African Union, most of Asia and South America have not been able to negotiate a vaccine for each of their citizens.

Similarly, rich countries have had privileged access to available doses, as measured by higher proportions of vaccinated people.

European Union 3DP per capita (€) **Population** covered by the amount of the country's procured Covid-19 Vaccines

'THE WORLD IS ON THE

CATASTROPHIC MORAL

FAILURE - AND THE PRICE

OF THIS FAILURE WILL BE

PAID WITH LIVES AND

LIVELIHOODS IN THE

WORLD'S POOREST

COUNTRIES."

Tedros Adhanom


BRINK OF A

*Accounting for the vaccines developed by the following manufacturers:

Pfizer **BioNTech** 22,83%


14,72% Johnson & Johnson 10,22% Sinovac 7,64% SputnikV 7,10%


Moderna



Proportion of citizens vaccinated in the country (%)

There is a clear cluster of less privileged countries towards the origin of the plot, meaning they were not able to buy enough vaccines to cover their population. Likewise, their access to current doses is restricted. Densely populated areas in Africa and India seem to have been able to purchase few doses of the vaccine and to vaccinate very few people. This showcases the moral catastrophe that the fight for the Covid-19 vaccine has caused. The unequal distribution of the vaccine may also cause harm to the efforts made so far to control the pandemic. The inequalities are also highlighted in price, as the variance further showcases the global inequitable access to covid-19 vaccines.





Authors: Daniel Correia - M20200665 Henrique Costa - M20200652

- Procurement Data: <u>Launch and Scale Faster</u>, Health Innovation Center, Duke University

Data adapted from (last update on 19/03/2021):

Joana Rafael - M20200588 Ricardo Santos - M20200620